We demonstrated that an aqueous extract of dried immature fruit of Poncirus trifoliate (PF-W) produces relaxation of intestinal smooth muscle using the ileac strips of a rat. Furthermore, the underlying mechanism of its relaxant activity was investigated. PF-W was prepared using the standard extraction protocol. A 1.5 -2 cm long rat ileac strip was placed in an organ bath with Tyrode's solution and smooth muscle contractility was recorded by connecting it to a force transducer. Various compounds were added to the organ baths, and changes in muscular contractility were measured. PF-W concentration-dependently induced relaxation of rat ileac strips that were contracted both spontaneously and via acetylcholine treatment. Various potassium channel blockers did not inhibit the relaxation by PF-W. No difference in the effect of PF-W was observed between ileac strips treated with low (20 mM) and high concentrations (60 mM) of KCl. PF-W inhibited the contraction of rat ileac strips induced by extracellular calcium. PF-W acts as a potent smooth muscle relaxant, implicating its possible action as a rapid acting reliever for abdominal pains and a cure for intestinal convulsion. Considering that PF-W also exhibits prokinetic activity, its use in various gastrointestinal disorders seems promising.
PF-W is an aqueous extract of Poncirus Fructus, the dried immature fruit of Poncirus trifoliata (L.) Raf. (Rutaceae). PF-W has long been used as a remedy for either acute or chronic gastrointestinal (GI) disorders in eastern Asia [1] . PF-W continues to occupy a significant place in some over-the-counter drugs in Korea. Lee and colleagues first offered scientific evidence that the prokinetic activity of PF-W is based on its enhancement of the rate of food emptying in the gastrointestinal (GI) tract [2] . In further studies, the long-term administration of PF-W induced weight loss in rats, probably due to its enhanced prokinetic activity [3] . In a recent study, PF-W induced its prokinetic activity via 5-HT4 receptor activation [4] suggesting that PF-W is indeed a potent prokinetic agent.
Many people experience acute cryptogenic abdominal pains, abrupt vomiting or diarrhea in their daily lives. These acute GI disorders easily degenerate into chronic ones (e.g., irritable bowel syndrome, IBS) that involve uncomfortable constipation and sudden diarrhea if an effective treatment regimen is not followed [5] . Mosapride, levosulpiride, metoclopramide and domperidone represent GI drugs that are frequently used to treat GI disorders including chronic IBS. However, adverse effects such as supraventricular tachycardia [6] and QT-interval prolongation might be experienced by neonates [7] because of the use of these drugs. So, the idea of using natural herbal drugs that seem to demonstrate less adverse effects than chemically synthesized drugs has continued to increase in popularity for the treatment of numerous GI disorders.
Symptoms of various above-mentioned GI disorders are tightly linked to deterioration in GI motility. In most cases, prokinetic agents that induce contraction, such as mosapride, are widely used in clinical settings. Although the effectiveness of such smooth muscle constrictors may be potent, not all conditions will be improved by their application. For instance, spasmodic GI complaints are often treated with relaxants instead of constrictors [8] . This is because the spontaneous contraction-relaxation coupling rhythm, known as the migrating motor complex (MMC), governs coordinated intestinal motility [9] .
Interestingly, GI disorder patients who have been taking PF-W consistently reported a feeling of relief, as if the discomfort from the spasm has immediately relaxed. Although these statements are completely anecdotal, this suggests the possibility that as soon as the PF-W reaches the intestine, it exerts local relaxation. However, no study has yet investigated the promotion of relaxation by PF-W. Thus, the present study was conducted in order to explore the putative relaxation effect of PF-W by recording the changes in the contractile forces of isolated rat ileac strips. The potential underlying mechanisms were also pursued.
If a drug is a relaxant, it should exert its concentration-dependent relaxation activity on a normal rat ileac strip. So, we first tried to evaluate whether PF-W actually caused relaxation activity on normal ileac strips. The spontaneous contractility of the rat ileac strip was maintained for more than an hour when the PF-W had not been applied (data not shown). Both the maximal and minimal spontaneous contractility of the rat ileac strip, however, was decreased by the presence of PF-W in a concentration-dependent manner ( Figure 1A) . The EC 50 of the PF-W during spontaneous contraction of the rat ileac strip was 8.3 ± 1.6 mg/mL, and the maximal relaxation response 76.9 ± 3.6% ( Figure 1B) . Therefore, we confirmed that PF-W exerted a relaxation effect on smooth muscles in the isolated rat ileac strip.
As a first step in the mechanism study, we searched for the involvement of acetylcholine in the relaxant effect of PF-W. As a neurotransmitter, acetylcholine is released from nervous terminals to the receptors of smooth muscle and triggers a smooth muscle contraction cascade. Therefore, we concluded that if PF-W inhibited acetylcholine-induced contraction, it would be evident that PF-W would be a smooth muscle relaxant under physiological conditions. Thus, the relaxation effect of the PF-W must be verified under conditions where contraction is achieved by acetylcholine. Due to the rapid metabolizing action of acetylcholine esterase [10] , however, pretreatment with PF-W was necessary, followed thereafter by acetylcholine treatment. As shown in Figure 2 , it turned out that pretreatment with PF-W reduced the acetylcholineinduced contraction in a concentration-dependent manner ( Figure  2B , EC 50 = 1.7 mg/mL, maximal response by PF-W is 96.7 ± 2.0 %). Therefore, we found that the PF-W exerts a strong relaxation effect that can readily relax acetylcholine-induced contraction.
Because a relaxation effect of PF-W was observed (Figures 1 and 2) , the underlying mechanisms were further investigated. First, the involvement of potassium channels was examined. For this purpose, we measured the effect of PF-W on a 20 mM KCl-induced experimental ileac contraction [11] . As a result, PF-W relaxed the contraction in a concentration-dependent manner ( Figure 3A) , suggesting that PF-W may act as a potassium channel opener. Therefore, several potassium channel blockers, such as BaCl 2 , TEA, glibenclamide, and apamin, were used to pretreat the preparation to investigate the possibility. However, it turned out that all the potassium channel blockers used failed to block the relaxation effect of PF-W ( Figure 3B ). Considering that concentrations of all the blockers were in a sufficient range to block the potassium channel [12] it was suggested that PF-W was less likely to interact with potassium channels to accomplish relaxation in the rat ileac strips.
Because voltage-gated calcium channels largely govern smooth muscle contraction, the possible involvement of these in smooth muscle-relaxation was then investigated. To achieve this goal, a high concentration of KCl (60 mM) was applied to the extracellular medium, which activated voltage-gated calcium channels [13] , resulting in spasm-like smooth muscle contraction. As shown in Figure 4A , the high KCl indeed induced muscle contraction, which was concentration-dependently inhibited by the PF-W treatment. However, the relaxation potency of the PF-W was almost identical to that of low (20 mM) KCl-induced conditions (Fig. 4B) , implying that the high KCl-induced contraction was less likely to be achieved by voltage-gated Ca 2+ channels. These data indicate that the relaxation induced by the PF-W did not occur via an inhibition of the voltage-gated calcium channels.
Because the involvement of potassium and calcium channels seemed less likely, the involvement of extracellular calcium ions in the relaxation by PF-W was examined. For this purpose, extracellular calcium was gradually applied to evoke contraction; extracellular CaCl 2 concentration-dependently induced strong contractions ( Figure 5A ), but these induced contractile forces were concentration-dependently blocked by pretreatment with PF-W ( Figure 5A and 5B, EC 50 = 6 mM (Control), 14.8 mM (PF-W 5 mg/mL), 692 mM (PF-W 10 mg/mL). These data indicate that PF-W interferes with extracellular calcium ions, which may play critical roles in the smooth muscle contraction cascade.
The present study clearly revealed that PF-W was a strong promoter of relaxation for the rat ileac strip during spontaneous contraction ( Figure 1 contraction, indicating that PF-W is a potent relaxant at least for the rat ileac strips tested here. Meanwhile, the exact relaxation mechanism of PF-W can be estimated from various perspectives. One may argue that the relaxant effect of PF-W might have come from the higher osmolarity of the PF-W solution. In fact, the osmolarity of PF-W (10 mg/mL) was around 320 mOsm/L, which seemed slightly hypertonic to normal buffers (around 300 mOsm/L). However, in our preliminary experiments, we found that a more hypertonic glucose solution (341 mOsm/L) never induced relaxation (n = 3, data not shown), suggesting that osmolarity is not the driving force of PF-W relaxation.
Many biophysical pathways -ion-channels on smooth muscular cells, the sympathetic nervous system and the parasympathetic nervous system -are known to be involved in the relaxation of intestinal smooth muscles. Generally, it is not easy to elucidate the exact mechanism of relaxation, particularly for an extract of natural products like PF-W, because these consist of various single compounds. In such cases, it is generally accepted that the first step is to analyze the relaxation activity in association with ion channels.
Thus, the effect of PF-W on the ion channels was then examined. Smooth muscle relaxation can be achieved by either a) enhancement of the repolarizing current ("potassium current") or b) inhibition of the depolarizing current ("calcium current") [15] . Specifically, the repolarizing current of the potassium ion is promoted by the opening of voltage-gated potassium channels, while the inhibition of the depolarizing calcium current is obtained via an inhibition of the voltage-gated calcium channels [16] . Therefore, in the present study, we tried to identify whether PF-W exerts its relaxation via these mechanisms.
To activate preferentially voltage-gated potassium channels, 20 mM KCl ("low potassium") was applied, which induced contraction in the rat ileac strip, as expected. Then, various potassium channel blockers, such as TEA, BaCl 2 , glibenclamide, and apamin, were tested with PF-W. This experimental scheme was based on a report showing that a potassium channel opener inhibits contractions induced by low-potassium ion concentration (<20 mM) [11] . TEA, a non-selective potassium channel blocker, has a unique molecular structure that easily binds with the core structures of a vast variety of potassium channels [17] . Other agents, like BaCl 2 , glibenclamide, and apamin [18] , were used to block K IR , K ATP , and SK ca channels that cannot be blocked by TEA, respectively [19] . In the present study, none of these blockers affected the relaxation of the PF-W, suggesting that the relaxation mechanism of PF-W is less likely to be mediated via potassium channel opening. Drugs that act on the potassium channel have the possibility of inducing side effects, such as cardiac arrhythmia [20] , and cisapride was withdrawn from the market for that reason. Contrary to the action of these drugs, PF-W appears to have clinical benefits in terms of cardiac side effects. Moreover, PF-W has been known not to act on the hERG channel [4] , which is associated with this particular type of side effect. To investigate the possible interactions with voltage-gated calcium channels, 60 mM KCl ("high potassium") was applied to induce contraction. However, as shown in Figure 4B , the relaxation pattern of the PF-W was almost identical to that of 20 mM KCl ("low potassium"), suggesting that the action of the PF-W is not exerted via an inhibition of calcium channels. Thus, it could be interpreted that PF-W is not likely to inhibit directly the voltage-gated calcium channels that are required for contraction. Although further experiments are mandatory in order to pinpoint the exact relationship between these channels, it could be summarized that PF-W neither opens nor blocks calcium channels in order to exert its relaxation effect.
To further identify how PF-W interacts with smooth muscle contraction and/or relaxation processes, the role of extracellular calcium was tested under the experimental conditions previously mentioned [21] . Considering that intracellular calcium is essential for smooth muscle contraction [22], the current experimental conditions were applied in order to deplete calcium stores in the sarcoplasmic reticulum. Thus, the calcium store depletion provided an environment whereby the contraction could only be achieved by extracellular calcium influx. As shown in Figure 5 , extracellular calcium concentration-dependently contracted the rat ileac strip, implying that the extracellular calcium moved into the intracellular region. When 5 mg/mL of PF-W was used to pretreat before the addition of extracellular calcium, however, the contraction induced by the extracellular calcium was dramatically reduced compared with that of the control group. Moreover, 10 mg/mL of PF-W almost completely abolished the contraction by extracellular calcium. Therefore, it is evident that PF-W has the ability to inhibit contraction that is induced by calcium. Because PF-W was found to be less likely to inhibit voltage-gated calcium channels (Figure 4) , the chances are that it does not directly block calcium influx via an action on ion channels in the contraction process. Rather, it is plausible that PF-W may exert its effect somewhere in the signaling cascade after the calcium influx, thereby achieving relaxation. For instance, it could be possible that PF-W may interfere with the calcium-calmodulin coupling required for muscular contraction. However, further studies, including the involvement of nervous systems, are necessary to unravel the exact mechanism, and we believe that it is beyond the scope of the present study using the current experimental systems.
In our previous study, we found that PF-W was a potent prokinetic agent that strongly enhanced intestinal motility [2] . The prokinetic activities, however, were often interpreted as smooth muscle contraction rather than relaxation [23] . Indeed, cisapride, which is a potent prokinetic agent, is well known for its strong smooth muscle contractile activity [24] , supporting the idea that contraction leads to prokinetic action. Moreover, we found that PF-W also activates the 5-HT4 receptor [4] , which is the same molecular target that cisapride stimulates to exert its prokinetic effect. In this regard, the current finding that PF-W has a strong "relaxant" effect might be seen as a result that conflicts with our previous reports. However, we should restate that PF-W is a natural mixture containing a wide variety of compounds. Thus, it is possible that the putative relaxant ingredient could co-exist with the compound that is responsible for contraction side-by-side in PF-W. Furthermore, since the ileac strip cannot perfectly mimic the natural environment of the small intestine, with its complicated interactions with the nervous system, it is also likely that the contraction activity of PF-W was not observed under the current ex vivo experimental conditions. In addition, it is plausible that relaxation combined with contraction ironically may enhance the intestinal motility. This may be true because the migrating motor complex (MMC) is comprised of a spontaneous contraction-relaxation coupling rhythm, which maintains harmony with the nervous signals from the myenteric plexus or the central nervous system [25] . Therefore, it could be true that PF-W exerts its prokinetic action via a strengthening of the contraction-relaxation rhythm in MMC. As the single compounds that are responsible for the relaxation and contraction in the PF-W remain elusive, only further identification will clarify the exact prokinetic mechanism of the PF-W.
The rapid onset of action is a desirable effect for some drugs such as pain relievers for stomach ache that requires an instant effect. Anecdotal evidence from Korean patients who took oral PF-W suggests that the stomach pain was rapidly relieved after administration. In the present study, we assumed that the relief was associated with the relaxation of the intestinal smooth muscle. The smooth muscle-relaxation effect (this study), as well as the prokinetic activity [3] [4] of PF-W might explain why PF-W has long been the drug of choice for various intestinal disorders in eastern Asia.
In the present study, PF-W clearly exerted potent smooth muscle relaxation activity on an isolated rat ileac strip. It seems that the relaxation was mediated neither by the blocking of potassium nor calcium channels that had been gated by voltage changes. Rather, we found that PF-W exerted its relaxation action via an inhibition of particular signaling pathways after the calcium influx. Considering that PF-W also possesses a prokinetic activity, there is little doubt that PF-W is a promising remedy for the treatment of a wide variety of gastrointestinal diseases.
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Experimental
Plant material and extract preparation: The PF-W was obtained by following previously described methods [2] . In brief, PF was purchased from the Gyungdong Market, a certified oriental drug store (Seoul, Korea). For future use and an additional supply of PF-W, reference specimens (No. EA239) were deposited at the Herbarium of the College of Pharmacy, Ewha Woman's University (Seoul, Korea). A PF sample (2 kg) was boiled in 30 L of distilled water at 100°C for 2 h. The yielded aqueous extract was filtered, vacuum concentrated, and lyophilized to yield a powder. The yield of PF-W was approximately 24.4%, w/w. The content of hesperidin in PF was determined in each PF-W sample using HPLC, as previously described, to assure the quality of the product [2] . The hesperidin content of PF-W was calculated to be 0.93 ± 0.01% (w/w, n = 3), which suggested a fairly stable content.
Chemicals: Acetylcholine hydrochloride, tetraethyl ammonium chloride (TEA), glibenclamide, barium chloride (BaCl 2 ), isoprenaline, apamin, ethylenediaminetetraacetic acid (EDTA), and all the constituents of Tyrode's solution -sodium chloride, potassium chloride, calcium chloride, potassium dihydrogen phosphate, magnesium chloride, sodium bicarbonate, and glucosewere obtained from Sigma (St. Louis, MO, USA).
Animals:
The research protocol (SNU-040910-2) was approved by the Animal Care and Use Committee of the College of Pharmacy, Seoul National University, and the institutional guidelines for the care and use of laboratory animals were followed throughout the study. Male Sprague-Dawley (SD) rats, 8 weeks of age and weighing 200 -300 g, were purchased from Orient Bio, Inc. (SeongNam, Korea). All rats were housed individually in clear plastic cages with controlled temperature (22 ± 2°C), humidity (55 ± 5%), and illumination cycles (lights on 7 a.m. -7 p.m.). Autoclavable rodent laboratory chow 5010 (Agribrands Purina Korea Inc., SungNam, Korea) and tap water were supplied ad libitum. All rats were acclimated to the housing conditions for one week prior to the experiments.
Preparation of ileac segments and tension measurement:
Male Sprague-Dawley rats weighing 200 -300 g were euthanized by CO 2 asphyxiation. Then the ileum (15 -20 cm long) proximal to the ileocecal valve was removed from each rat and the contents of the ileac lumen flushed with a physiological salt solution (Tyrode's solution). The phosphate-buffered Tyrode's solution (pH 7.35) was composed of (in mM) NaCl 145, KCl 5.4, MgCl 2 1, CaCl 2 1.5, NaH 2 PO 4 0.42, Na 2 HPO 4 1.81, and glucose 5. The prepared ileac segments (1.5 -2 cm long) were suspended in an organ bath, which contained 20 mL of thermostatically controlled (37°C) Tyrode's solution. The organ bath was aerated with a gas mixture of 95% O 2 and 5% CO 2 . One distal end of the segments was directly connected to a needle of the organ bath, and the other end was connected to an isometric force transducer (model FT-03; Grass instruments, Quincy, USA) via a cotton thread to record the contractile forces of the longitudinal smooth muscle of the prepared ileac segment. Data were acquired using PowerLab 4/35 (AD instruments, Sydney, Australia) and were analyzed using LabChart software (AD instruments, Sydney, Australia). Each segment was preloaded with 0.25 g of tension, and this was gradually increased by 0.25 g, to a final tension of 1 g during the course of 1 h. The Tyrode's solution was changed (washed) between the increases in tension. Three ileac segments were obtained from the same rat and the segment that showed the strongest spontaneous contractile force and constant spontaneous activity was selected for the experiment. n values indicate the number of ileac segments from different rats.
Effect of PF-W on the ileac segment contraction: After 60 min equilibration at 1 g of preload, the PF-W (0.01; 0.1; 1; 5; and, 10 mg/mL dissolved in Tyrode's solution) was added to the organ bath cumulatively. The concentrations seemed comparable with, or lower than, the possible clinical concentration of PF-W in the human intestine, considering a traditional dose of PF-W (i.e., once daily oral dose of 2-75 g, [2] ) and the volume of human intestinal fluid (i.e., < 2 L [26] ), which corresponds to 1 ~ 37 mg/mL of PF-W approximately. The incubation time was 10 min for each concentration. The ileac contraction was induced according to the method of Dela Peña et al. [14] by treating the ileac segment with acetylcholine (1 µM ) and washing twice with Tyrode's solution (5 min period for each washing). The addition of acetylcholine and the washing procedure were repeated 3 times for each ileac segment to obtain control of the contractions. To verify ion channel involvement, either 20 mM KCl (low potassium) or 60 mM KCl (high potassium) was added. Ten min after the first addition of KCl, the organ bath was washed twice (5 min interval). Then the same concentration of KCl was again added to check the desensitization. The contractile force reached a plateau 20 min after the second addition of KCl. One mM of TEA, 10 µM of BaCl 2 , 10 µM of glibenclamide, and 100 nM of apamin were used to pretreat 10 min before the addition of PF-W, if needed. After all these recordings, isoprenaline (100 µM), a smooth muscle relaxant with a β 2 -adrenergic receptor agonism, was used for treatment. In previous studies, this concentration of isoprenaline had produced maximal relaxation of ileac segments [14] . The contractile force 10 min after adding isoprenaline reached a plateau that was considered to be 100% relaxation, which was regarded as E max for the relaxation activity of an ileac segment.
Effect of extracellular calcium on ileac contraction under calcium-store depletion: Ileac segments were equilibrated in normal Tyrode's solution for 60 min with 1 g of preload, and the solution was changed with K + -rich, Ca 2+ -free Tyrode's solution (in mM; NaCl 79.6, KCl 60, MgCl 2 1, NaH 2 PO 4 0.42, Na 2 HPO 4 1.81, glucose 5, EDTA 2, pH 7.35). To deplete calcium stores, 1 µM acetylcholine had been repeatedly applied until no contractile response was obtained. Then, 16 mM CaCl 2 was added to induce the maximal contractile response [21] . After washing twice with K + -rich Ca 2+ -free Tyrode's solution at 5 min intervals, treatment with PF-W (5 or 10 mg/mL) was performed for 10 min. CaCl 2 was then cumulatively added ranging from 1 ~ 16 mM.
Data analysis:
The contractile force after 1 h of equilibration with 1 g preload was defined as 0% relaxation. For the acetylcholineinduced contraction, the maximal contractile force was defined as 0%. In all other cases, the plateau was defined as 0% relaxation, while isoprenaline-induced relaxation was defined as 100%. All data are expressed as the means ± the standard error of the mean (S.E.M)
